View Document Preview and Link Document Date: 2015-04-22 09:32:40 Open Document File Size: 567,14 KB Share Result on Facebook
City Berlin / NOX / / Company NOXXON Pharma AG / Drugs NOXXON Pharma / Bayer AG / NOXXON (since 1997) Aram Mangasarian / Astra / Ligand / Media Contact Business Development NOXXON Pharma AG / / Continent Europe / / Country Germany / United States / / Currency USD / / / Event FDA Phase / / Facility Biologically stable / Large pipeline / clinic Physicochemical / / / IndustryTerm biopharmaceutical / pharmaceutical industry / chemical process / chemical mirroring technology / therapeutic applications / / MedicalCondition specifically diabetic nephropathy / proteinuria / tumor / pilot Phase 2a anemia / anemic cancer / Diabetic Nephropathy / Metastasis / glioma / solid tumors / Diabetes / relapsed/refractory Multiple Myeloma / chronic inflammation / Chronic Disease NOX-A12 / chronic disease / Inflammation / Anemia / glioblastoma / / MedicalTreatment chemotherapy / Immunostimulation / / Organization American Society of Hematology / Executive Board / / Person Iain Buchanan / Matthias Baumann / Sven Klussmann / Walter Wenninger / Emmanuelle Delabre Aram Mangasarian / / / Position CEO / co-founder / mediator / production and chemical process Management Intellectual Property Chairman of the Supervisory Board / General / / Product Glucagon / E36 / A12 / CXCL12 / H94 / / Technology Pharmacokinetics / chemical mirroring technology / antibodies / chemotherapy / Patents covering mirroring technologies / Spiegelmer technology / / URL www.noxxon.com / / SocialTag 
Turning Spiegelmers into Drugs NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers*, the chemically synthesized, immunologically passive a